@article{deluisRoleRs6923761Gene2015,
  title = {Role of Rs6923761 Gene Variant in Glucagon-like Peptide 1 Receptor in Basal {{GLP-1}} Levels, Cardiovascular Risk Factor and Serum Adipokine Levels in Na{\"i}ve Type 2 Diabetic Patients},
  author = {{de Luis}, D. A. and Aller, R. and Izaola, O. and Bachiller, R.},
  year = {2015},
  month = feb,
  journal = {Journal of Endocrinological Investigation},
  volume = {38},
  number = {2},
  pages = {143--147},
  issn = {1720-8386},
  doi = {10.1007/s40618-014-0161-y},
  abstract = {BACKGROUND: Role of GLP-1 variants on basal GLP-1 levels, body weight and cardiovascular risk factors remains unclear in patients with diabetes mellitus type 2. OBJECTIVE: Our aim was to analyze the effects of rs6923761 GLP-1 receptor polymorphism on body weight, cardiovascular risk factors, basal GLP-1 levels and serum adipokine levels in na{\"i}ve patients with diabetes mellitus type 2. DESIGN: A sample of 104 na{\"i}ve patients with diabetes mellitus type 2 was enrolled in a prospective way. Basal fasting glucose, c-reactive protein (CRP), insulin, insulin resistance (HOMA), total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides concentration, basal GLP-1, HbA1c and adipokines (leptin, adiponectin, resistin) levels were determined. Weights, body mass index, waist circumference, fat mass by bioimpedance and blood pressure measures were measured. RESULTS: Forty-nine patients (47.1\%) had the genotype GG and 55 (52.9\%) diabetic subjects had the next genotypes; GA (44 patients, 42.3\%) or AA (11 study subjects, 10.6\%) (second group). In A allele carriers, basal GLP-1 levels were higher than non-carriers (2.9 {$\pm$} 2.1 ng/ml; p {$<$} 0.05). No differences were detected between both genotype groups. CONCLUSION: Our cross-sectional study revealed an association between the rs6923761 GLP-1 receptor polymorphism (A allele carriers) and basal GLP-1 levels in na{\"i}ve patients with diabetes mellitus type 2.},
  langid = {english},
  pmid = {25200998},
  keywords = {Adipokines,Adult,Aged,Cardiovascular Diseases,Cardiovascular risk factors,Cross-Sectional Studies,Diabetes mellitus type 2,{Diabetes Mellitus, Type 2},Female,Genetic Variation,Glucagon-like peptide 1,Glucagon-Like Peptide 1,Glucagon-like peptide 1 receptor,Glucagon-Like Peptide-1 Receptor,Humans,Male,Middle Aged,Prospective Studies,Risk Factors,rs6923761}
}

@article{gaoHumanGLP1RVariants2023,
  title = {Human {{GLP1R}} Variants Affecting {{GLP1R}} Cell Surface Expression Are Associated with Impaired Glucose Control and Increased Adiposity},
  author = {Gao, Wenwen and Liu, Lei and Huh, Eunna and Gbahou, Florence and Cecon, Erika and Oshima, Masaya and Houz{\'e}, Ludivine and Katsonis, Panagiotis and Hegron, Alan and Fan, Zhiran and Hou, Guofei and Charpentier, Guillaume and Boissel, Mathilde and Derhourhi, Mehdi and Marre, Michel and Balkau, Beverley and Froguel, Philippe and Scharfmann, Raphael and Lichtarge, Olivier and Dam, Julie and Bonnefond, Am{\'e}lie and Liu, Jianfeng and Jockers, Ralf},
  year = {2023},
  month = oct,
  journal = {Nature Metabolism},
  volume = {5},
  number = {10},
  pages = {1673--1684},
  publisher = {{Nature Publishing Group}},
  issn = {2522-5812},
  doi = {10.1038/s42255-023-00889-6},
  urldate = {2024-01-18},
  abstract = {The glucagon-like peptide 1 receptor (GLP1R) is a major drug target with several agonists being prescribed in individuals with type 2 diabetes and obesity1,2. The impact of genetic variability of GLP1R on receptor function and its association with metabolic traits are unclear with conflicting reports. Here, we show an unexpected diversity of phenotypes ranging from defective cell surface expression to complete or pathway-specific gain of function (GoF) and loss of function (LoF), after performing a functional profiling of 60 GLP1R variants across four signalling pathways. The defective insulin secretion of GLP1R LoF variants is rescued by allosteric GLP1R ligands or high concentrations of exendin-4/semaglutide in INS-1 823/3 cells. Genetic association studies in 200,000 participants from the UK Biobank show that impaired GLP1R cell surface expression contributes to poor glucose control and increased adiposity with increased glycated haemoglobin A1c and body mass index. This study defines impaired GLP1R cell surface expression as a risk factor for traits associated with type 2 diabetes and obesity and provides potential treatment options for GLP1R LoF variant carriers.},
  copyright = {2023 The Author(s), under exclusive licence to Springer Nature Limited},
  langid = {english},
  keywords = {Genetic association study,Metabolism,Next-generation sequencing,Obesity,Risk factors}
}

@article{hammoudPancreasContrastingCardiometabolic2023,
  title = {Beyond the Pancreas: Contrasting Cardiometabolic Actions of {{GIP}} and {{GLP1}}},
  shorttitle = {Beyond the Pancreas},
  author = {Hammoud, Rola and Drucker, Daniel J.},
  year = {2023},
  month = apr,
  journal = {Nature Reviews Endocrinology},
  volume = {19},
  number = {4},
  pages = {201--216},
  publisher = {{Nature Publishing Group}},
  issn = {1759-5037},
  doi = {10.1038/s41574-022-00783-3},
  urldate = {2024-01-18},
  abstract = {Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1) exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion. The emergence of GIP receptor (GIPR){\textendash}GLP1 receptor (GLP1R) co-agonists has fostered growing interest in the actions of GIP and GLP1 in metabolically relevant tissues. Here, we update concepts of how these hormones act beyond the pancreas. The actions of GIP and GLP1 on liver, muscle and adipose tissue, in the control of glucose and lipid homeostasis, are discussed in the context of plausible mechanisms of action. Both the GIPR and GLP1R are expressed in the central nervous system, wherein receptor activation produces anorectic effects enabling weight loss. In preclinical studies, GIP and GLP1 reduce atherosclerosis. Furthermore, GIPR and GLP1R are expressed within the heart and immune system, and GLP1R within the kidney, revealing putative mechanisms linking GIP and GLP1R agonism to cardiorenal protection. We interpret the clinical and mechanistic data obtained for different agents that enable weight loss and glucose control for the treatment of obesity and type 2 diabetes mellitus, respectively, by activating or blocking GIPR signalling, including the GIPR{\textendash}GLP1R co-agonist tirzepatide, as well as the GIPR antagonist{\textendash}GLP1R~agonist AMG-133. Collectively, we update translational concepts of GIP and GLP1 action, while highlighting gaps, areas of uncertainty and controversies meriting ongoing investigation.},
  copyright = {2022 Springer Nature Limited},
  langid = {english},
  keywords = {Endocrine system,Endocrine system and metabolic diseases},
  file = {/Users/xx20081/Zotero/storage/IK2GTDNE/Hammoud and Drucker - 2023 - Beyond the pancreas contrasting cardiometabolic a.pdf}
}

@misc{handleyRareVariantsGlucagonlike2023,
  title = {Rare Variants of the Glucagon-like Peptide-1 Receptor ({{GLP1R}}) Gene Are Overrepresented in a Severe Obesity Cohort and Associated with Type 2 Diabetes in the {{UK Biobank}}},
  author = {Handley, Dale and Almansoori, Sumaya and Sato, Mitra S. and Amin, Hasnat and Alsters, Suzanne and Chahal, Harvinder and Purkayastha, Sanjay and Murphy, Kevin G. and van Haelst, Mieke and le Roux, Carel W. and Tan, Tricia and Walters, Robin G. and Drenos, Fotios and Blakemore, Alexandra I.},
  year = {2023},
  month = may,
  pages = {2023.05.22.23290347},
  publisher = {{medRxiv}},
  doi = {10.1101/2023.05.22.23290347},
  urldate = {2024-01-18},
  abstract = {Introduction Glucagon-like peptide 1 (GLP1) agonists are highly effective agents for the treatment of obesity and type 2 diabetes (T2D). GLP-1 is also implicated in outcomes of bariatric surgery, including appetite changes and T2D remission. Rare, potentially deleterious mutations in the glucagon-like peptide 1 receptor gene (GLP1R) may, therefore, have important implications for pathogenesis of obesity and T2D, and for response to therapeutic interventions. Methods A custom Axion genotyping array, including 117 rare predicted-deleterious GLP1R mutations (MAF{$<$}0.01 in gnomAD, CADD-PHRED m {$>$}= 15), was used to screen 1714 unrelated adults with BMI {$>$}35 kg/m2 from the PMMO study. We also examined the UK Biobank (UKB) exome sequence dataset for rare, predicted-deleterious GLP1R variants and tested their effects on weight and glycaemia-related traits. Results Thirty-four PMMO participants carried one of the 117 GLP1R variants screened (11 might have been expected using the sum of their gnomAD control MAFs). These 8 variants were associated with T2D in the UKB and subsequent gene-level analysis of the UKB exome sequence dataset (629/39,274 carriers) confirmed that rare GLP1R variants are associated with increased risk of T2D (OR=1.58), as well as with higher HbA1c levels (p= 0.039). Furthermore, our data highlight a potential interaction of these variants with body mass index. Conclusion Rare, potentially deleterious GLP1R mutations is associated with increased T2D risk, as well as higher HbA1c in UKB participants without diabetes. Future studies should examine the implications of GLP1R mutations for response to GLP1 agonist treatment and explore the observed interactions with obesity in T2D risk, including in larger cohorts with obesity.},
  archiveprefix = {medRxiv},
  copyright = {{\textcopyright} 2023, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/8CEF79K3/Handley et al. - 2023 - Rare variants of the glucagon-like peptide-1 recep.pdf}
}

@article{lagouGWASRandomGlucose2023,
  title = {{{GWAS}} of Random Glucose in 476,326 Individuals Provide Insights into Diabetes Pathophysiology, Complications and Treatment Stratification},
  author = {Lagou, Vasiliki and Jiang, Longda and Ulrich, Anna and Zudina, Liudmila and Gonz{\'a}lez, Karla Sofia Guti{\'e}rrez and Balkhiyarova, Zhanna and Faggian, Alessia and Maina, Jared G. and Chen, Shiqian and Todorov, Petar V. and Sharapov, Sodbo and David, Alessia and Marullo, Letizia and M{\"a}gi, Reedik and Rujan, Roxana-Maria and Ahlqvist, Emma and Thorleifsson, Gudmar and Gao, {$H$}e and {$E$}vangelou, {$E$}vangelos and Benyamin, Beben and Scott, Robert A. and Isaacs, Aaron and Zhao, Jing Hua and Willems, Sara M. and Johnson, Toby and Gieger, Christian and Grallert, Harald and Meisinger, Christa and {M{\"u}ller-Nurasyid}, Martina and Strawbridge, Rona J. and Goel, Anuj and Rybin, Denis and Albrecht, Eva and Jackson, Anne U. and Stringham, Heather M. and Corr{\^e}a, Ivan R. and {Farber-Eger}, Eric and Steinthorsdottir, Valgerdur and Uitterlinden, Andr{\'e} G. and Munroe, Patricia B. and Brown, Morris J. and Schmidberger, Julian and Holmen, Oddgeir and Thorand, Barbara and Hveem, Kristian and Wilsgaard, Tom and Mohlke, Karen L. and Wang, Zhe and {Aleksey Shmeliov} and {den Hoed}, Marcel and Loos, Ruth J. F. and Kratzer, Wolfgang and Haenle, Mark and Koenig, Wolfgang and Boehm, Bernhard O. and Tan, Tricia M. and Tomas, Alejandra and Salem, Victoria and Barroso, In{\^e}s and Tuomilehto, Jaakko and Boehnke, Michael and Florez, Jose C. and Hamsten, Anders and Watkins, Hugh and Nj{\o}lstad, Inger and Wichmann, H.-Erich and Caulfield, Mark J. and Khaw, Kay-Tee and {van Duijn}, Cornelia M. and Hofman, Albert and Wareham, Nicholas J. and Langenberg, Claudia and Whitfield, John B. and Martin, Nicholas G. and Montgomery, Grant and Scapoli, Chiara and Tzoulaki, Ioanna and Elliott, Paul and Thorsteinsdottir, Unnur and Stefansson, Kari and Brittain, Evan L. and McCarthy, Mark I. and Froguel, Philippe and Sexton, Patrick M. and Wootten, Denise and Groop, Leif and Dupuis, Jos{\'e}e and Meigs, James B. and Deganutti, Giuseppe and Demirkan, Ayse and Pers, Tune H. and Reynolds, Christopher A. and Aulchenko, Yurii S. and Kaakinen, Marika A. and Jones, Ben and Prokopenko, Inga},
  year = {2023},
  month = sep,
  journal = {Nature Genetics},
  volume = {55},
  number = {9},
  pages = {1448--1461},
  publisher = {{Nature Publishing Group}},
  issn = {1546-1718},
  doi = {10.1038/s41588-023-01462-3},
  urldate = {2024-01-15},
  abstract = {Conventional measurements of fasting and postprandial blood glucose levels investigated in genome-wide association studies (GWAS) cannot capture the effects of DNA variability on `around the clock' glucoregulatory processes. Here we show that GWAS meta-analysis of glucose measurements under nonstandardized conditions (random glucose (RG)) in 476,326 individuals of diverse ancestries and without diabetes enables locus discovery and innovative pathophysiological observations. We discovered 120 RG loci represented by 150 distinct signals, including 13 with sex-dimorphic effects, two cross-ancestry and seven rare frequency signals. Of these, 44 loci are new for glycemic traits. Regulatory, glycosylation and metagenomic annotations highlight ileum and colon tissues, indicating an underappreciated role of the gastrointestinal tract in controlling blood glucose. Functional follow-up and molecular dynamics simulations of lower frequency coding variants in glucagon-like peptide-1 receptor (GLP1R), a type 2 diabetes treatment target, reveal that optimal selection of GLP-1R agonist therapy will benefit from tailored genetic stratification. We also provide evidence from Mendelian randomization that lung function is modulated by blood glucose and that pulmonary dysfunction is a diabetes complication. Our investigation yields new insights into the biology of glucose regulation, diabetes complications and pathways for treatment stratification.},
  copyright = {2023 The Author(s)},
  langid = {english},
  keywords = {Diseases,Genetics},
  file = {/Users/xx20081/Zotero/storage/BQU5WB5U/Lagou et al. - 2023 - GWAS of random glucose in 476,326 individuals prov.pdf}
}

@article{melchiorsenRareHeterozygousLossofFunction2023,
  title = {Rare {{Heterozygous Loss-of-Function Variants}} in the {{Human GLP-1 Receptor Are Not Associated With Cardiometabolic Phenotypes}}},
  author = {Melchiorsen, Josefine U. and S{\o}rensen, Kimmie V. and {Bork-Jensen}, Jette and Kizilkaya, H{\"u}s{\"u}n S. and Gasbjerg, L{\ae}rke S. and Hauser, Alexander S. and Rungby, J{\o}rgen and S{\o}rensen, Henrik T. and Vaag, Allan and Nielsen, Jens S. and Pedersen, Oluf and Linneberg, Allan and Hartmann, Bolette and Gjesing, Anette P. and Holst, Jens J. and Hansen, Torben and Rosenkilde, Mette M. and Grarup, Niels},
  year = {2023},
  month = oct,
  journal = {The Journal of Clinical Endocrinology and Metabolism},
  volume = {108},
  number = {11},
  pages = {2821--2833},
  issn = {1945-7197},
  doi = {10.1210/clinem/dgad290},
  abstract = {CONTEXT: Lost glucagon-like peptide 1 receptor (GLP-1R) function affects human physiology. OBJECTIVE: This work aimed to identify coding nonsynonymous GLP1R variants in Danish individuals to link their in vitro phenotypes and clinical phenotypic associations. METHODS: We sequenced GLP1R in 8642 Danish individuals with type 2 diabetes or normal glucose tolerance and examined the ability of nonsynonymous variants to bind GLP-1 and to signal in transfected cells via cyclic adenosine monophosphate (cAMP) formation and {$\beta$}-arrestin recruitment. We performed a cross-sectional study between the burden of loss-of-signaling (LoS) variants and cardiometabolic phenotypes in 2930 patients with type 2 diabetes and 5712 participants in a population-based cohort. Furthermore, we studied the association between cardiometabolic phenotypes and the burden of the LoS variants and 60 partly overlapping predicted loss-of-function (pLoF) GLP1R variants found in 330 566 unrelated White exome-sequenced participants in the UK Biobank cohort. RESULTS: We identified 36 nonsynonymous variants in GLP1R, of which 10 had a statistically significant loss in GLP-1-induced cAMP signaling compared to wild-type. However, no association was observed between the LoS variants and type 2 diabetes, although LoS variant carriers had a minor increased fasting plasma glucose level. Moreover, pLoF variants from the UK Biobank also did not reveal substantial cardiometabolic associations, despite a small effect on glycated hemoglobin A1c. CONCLUSION: Since no homozygous LoS nor pLoF variants were identified and heterozygous carriers had similar cardiometabolic phenotype as noncarriers, we conclude that GLP-1R may be of particular importance in human physiology, due to a potential evolutionary intolerance of harmful homozygous GLP1R variants.},
  langid = {english},
  pmcid = {PMC10584003},
  pmid = {37235780},
  keywords = {Cardiovascular Diseases,Cross-Sectional Studies,{Diabetes Mellitus, Type 2},functional study,genetic association,GLP-1R,Glucagon-Like Peptide 1,glucagon-like peptide 1 receptor,Glucagon-Like Peptide-1 Receptor,Humans,Phenotype,type 2 diabetes},
  file = {/Users/xx20081/Zotero/storage/XEYP9JP7/Melchiorsen et al. - 2023 - Rare Heterozygous Loss-of-Function Variants in the.pdf}
}

@misc{MendelianRandomizationStudying,
  title = {Mendelian Randomization for Studying the Effects of Perturbing Drug Targets - {{PMC}}},
  urldate = {2024-01-18},
  howpublished = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903200/},
  file = {/Users/xx20081/Zotero/storage/23QL9FZU/PMC7903200.html}
}

@article{michalowskaAssociationGLP1RVariants2022,
  title = {Association of {{GLP1R}} Variants Rs2268641 and Rs6923761 with Obesity and Other Metabolic Parameters in a {{Polish}} Cohort},
  author = {Micha{\l}owska, Joanna and {Miller-Kasprzak}, Ewa and {Seraszek-Jaros}, Agnieszka and Mostowska, Adrianna and Bogda{\'n}ski, Pawe{\l}},
  year = {2022},
  month = oct,
  journal = {Frontiers in Endocrinology},
  volume = {13},
  pages = {1000185},
  issn = {1664-2392},
  doi = {10.3389/fendo.2022.1000185},
  urldate = {2024-01-18},
  abstract = {Introduction Obesity is a complex disease associated with excessive fat accumulation and numerous metabolic complications. So far, many factors leading to the development of this disorder have been identified, including genetic susceptibility. Various studies linked GLP1R variants with anthropometric and metabolic parameters, suggesting the role of the variation in this gene in metabolic health. Objective The aim of this study is to investigate the association of two single nucleotide variants of GLP1R gene, rs2268641 and rs6923761, with excessive weight, metabolic syndrome, anthropometric measurements and selected metabolic parameters. Methods Normal-weight subjects (n= 340, control group) and subjects with excessive body mass (n = 600, study group) participated in this study. For all participants, anthropometric measurements and metabolic parameters were collected, and genotyping of the two single nucleotide variants of GLP1R gene, rs2268641 and rs6923761, was performed using the high-resolution melting curve analysis. Results Significant differences in the genotype distribution of rs2268641 were found, where homozygous TT genotype was significantly less frequent in the study group with excessive body mass (OR=0.66; p=0.0298). For rs6923761, A allele and homozygous AA genotype were significantly more frequent in the study group with excessive weight than in the control group (OR=1.27; p=0.0239 and OR=1.69; p=0.0205, respectively). The association of studied variants with metabolic parameters was found for rs6923761. For this variant, AA carriers had higher body mass in comparison to GG carriers (p=0.0246), and AA carriers had higher glucose concentration in comparison to AG carriers (p=0.0498). We did not find an association of rs2268641 and rs6923761 with metabolic syndrome. Conclusion In our study, AA carriers of rs6923761 had higher risk of excessive body mass, whereas TT carriers of rs2268641 had lower risk of being overweight. Moreover, homozygous carriers of the minor allele of rs6923761 had higher glucose concentration in comparison to heterozygous subjects. None of the studied variants were associated with metabolic syndrome in the studied population.},
  pmcid = {PMC9626533},
  pmid = {36339410},
  keywords = {read},
  file = {/Users/xx20081/Zotero/storage/H6XXDNJY/Micha≈Çowska et al. - 2022 - Association of GLP1R variants rs2268641 and rs6923.pdf}
}

@article{patelMendelianRandomizationV0Updates2023,
  title = {{{MendelianRandomization}} v0.9.0: Updates to an {{R}} Package for Performing {{Mendelian}} Randomization Analyses Using Summarized Data},
  shorttitle = {{{MendelianRandomization}} v0.9.0},
  author = {Patel, Ashish and Ye, Ting and Xue, Haoran and Lin, Zhaotong and Xu, Siqi and Woolf, Benjamin and Mason, Amy M. and Burgess, Stephen},
  year = {2023},
  journal = {Wellcome Open Research},
  volume = {8},
  pages = {449},
  issn = {2398-502X},
  doi = {10.12688/wellcomeopenres.19995.1},
  abstract = {The MendelianRandomization package is a software package written for the R software environment that implements methods for Mendelian randomization based on summarized data. In this manuscript, we describe functions that have been added or edited in the package since version 0.5.0, when we last described the package and its contents. The main additions to the package since that time are: 1) new robust methods for performing Mendelian randomization, particularly in the cases of bias from weak instruments and/or winner's curse, and pleiotropic variants, 2) methods for performing Mendelian randomization with correlated variants using dimension reduction to summarize large numbers of highly correlated variants into a limited set of principal components, 3) functions for calculating first-stage F statistics, representing instrument strength, in both univariable and multivariable contexts, and with uncorrelated and correlated genetic variants. We also discuss some pragmatic issues relating to the use of correlated variants in Mendelian randomization.},
  langid = {english},
  pmcid = {PMC10616660},
  pmid = {37915953},
  keywords = {causal inference,genetic associations,genetic epidemiology,instrumental variable,Mendelian randomization,post-GWAS analysis,summarized data},
  file = {/Users/xx20081/Zotero/storage/BXD2DK6B/Patel et al. - 2023 - MendelianRandomization v0.9.0 updates to an R pac.pdf}
}

@misc{patelRobustUsePhenotypic2023,
  title = {Robust Use of Phenotypic Heterogeneity at Drug Target Genes for Mechanistic Insights: Application of Cis-Multivariable {{Mendelian}} Randomization to {{GLP1R}} Gene Region},
  shorttitle = {Robust Use of Phenotypic Heterogeneity at Drug Target Genes for Mechanistic Insights},
  author = {Patel, Ashish and Gill, Dipender and Shungin, Dmitry and Mantzoros, Christos S. and Knudsen, Lotte Bjerre and Bowden, Jack and Burgess, Stephen},
  year = {2023},
  month = jul,
  pages = {2023.07.20.23292958},
  publisher = {{medRxiv}},
  doi = {10.1101/2023.07.20.23292958},
  urldate = {2024-01-13},
  abstract = {Phenotypic heterogeneity at genomic loci encoding drug targets can be exploited by multivariable Mendelian randomization to provide insight on the pathways by which pharmacological interventions may affect disease risk. However, statistical inference in such investigations may be poor if overdispersion heterogeneity in measured genetic associations is unaccounted for. In this work, we first develop conditional F-statistics for dimension-reduced genetic associations that enable more accurate measurement of phenotypic heterogeneity. We then develop a novel extension for two-sample multivariable Mendelian randomization that accounts for overdispersion heterogeneity in dimension-reduced genetic associations. Our empirical focus is to use genetic variants in the GLP1R gene region to understand the mechanism by which GLP1R agonism affects coronary artery disease (CAD) risk. Colocalization analyses indicate that distinct variants in the GLP1R gene region are associated with body mass index and type 2 diabetes. Multivariable Mendelian randomization analyses that were corrected for overdispersion heterogeneity suggest that bodyweight lowering rather than type 2 diabetes liability lowering effects of GLP1R agonism are more likely contributing to reduced CAD risk. Tissue-specific analyses prioritised brain tissue as the most likely to be relevant for CAD risk, of the tissues considered. We hope the multivariable Mendelian randomization approach illustrated here is widely applicable to better understand mechanisms linking drug targets to diseases outcomes, and hence to guide drug development efforts.},
  archiveprefix = {medRxiv},
  copyright = {{\textcopyright} 2023, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/SKB3NCNQ/Patel et al. - 2023 - Robust use of phenotypic heterogeneity at drug tar.pdf}
}

@article{porcuMendelianRandomizationIntegrating2019,
  title = {Mendelian Randomization Integrating {{GWAS}} and {{eQTL}} Data Reveals Genetic Determinants of Complex and Clinical Traits},
  author = {Porcu, Eleonora and R{\"u}eger, Sina and Lepik, Kaido and Santoni, Federico A. and Reymond, Alexandre and Kutalik, Zolt{\'a}n},
  year = {2019},
  month = jul,
  journal = {Nature Communications},
  volume = {10},
  number = {1},
  pages = {3300},
  publisher = {{Nature Publishing Group}},
  issn = {2041-1723},
  doi = {10.1038/s41467-019-10936-0},
  urldate = {2024-01-18},
  abstract = {Genome-wide association studies (GWAS) have identified thousands of variants associated with complex traits, but their biological interpretation often remains unclear. Most of these variants overlap with expression QTLs, indicating their potential involvement in regulation of gene expression. Here, we propose a transcriptome-wide summary statistics-based Mendelian Randomization approach (TWMR) that uses multiple SNPs as instruments and multiple gene expression traits as exposures, simultaneously. Applied to 43 human phenotypes, it uncovers 3,913 putatively causal gene{\textendash}trait associations, 36\% of which have no genome-wide significant SNP nearby in previous GWAS. Using independent association summary statistics, we find that the majority of these loci were missed by GWAS due to power issues. Noteworthy among these links is educational attainment-associated BSCL2, known to carry mutations leading to a Mendelian form of encephalopathy. We also find pleiotropic causal effects suggestive of mechanistic connections. TWMR better accounts for pleiotropy and has the potential to identify biological mechanisms underlying complex traits.},
  copyright = {2019 The Author(s)},
  langid = {english},
  keywords = {Gene expression,Quantitative trait,Statistical methods},
  file = {/Users/xx20081/Zotero/storage/UY3XU6HV/Porcu et al. - 2019 - Mendelian randomization integrating GWAS and eQTL .pdf}
}

@article{schmidtGeneticDrugTarget2020,
  title = {Genetic Drug Target Validation Using {{Mendelian}} Randomisation},
  author = {Schmidt, Amand F. and Finan, Chris and {Gordillo-Mara{\~n}{\'o}n}, Maria and Asselbergs, Folkert W. and Freitag, Daniel F. and Patel, Riyaz S. and Tyl, Beno{\^i}t and Chopade, Sandesh and Faraway, Rupert and Zwierzyna, Magdalena and Hingorani, Aroon D.},
  year = {2020},
  month = jun,
  journal = {Nature Communications},
  volume = {11},
  number = {1},
  pages = {3255},
  publisher = {{Nature Publishing Group}},
  issn = {2041-1723},
  doi = {10.1038/s41467-020-16969-0},
  urldate = {2024-01-18},
  abstract = {Mendelian randomisation (MR) analysis is an important tool to elucidate the causal relevance of environmental and biological risk factors for disease. However, causal inference is undermined if genetic variants used to instrument a risk factor also influence alternative disease-pathways (horizontal pleiotropy). Here we report how the `no horizontal pleiotropy assumption' is strengthened when proteins are the risk factors of interest. Proteins are typically the proximal effectors of biological processes encoded in the genome. Moreover, proteins are the targets of most medicines, so MR studies of drug targets are becoming a fundamental tool in drug development. To enable such studies, we introduce a mathematical framework that contrasts MR analysis of proteins with that of risk factors located more distally in the causal chain from gene to disease. We illustrate key model decisions and introduce an analytical framework for maximising power and evaluating the robustness of analyses.},
  copyright = {2020 The Author(s)},
  langid = {english},
  keywords = {Drug development,Personalized medicine,Target validation},
  file = {/Users/xx20081/Zotero/storage/9MDIIWUS/Schmidt et al. - 2020 - Genetic drug target validation using Mendelian ran.pdf}
}

@misc{SystematicDifferencesDiscovery,
  title = {Systematic Differences in Discovery of Genetic Effects on Gene Expression and Complex Traits | {{Nature Genetics}}},
  urldate = {2023-12-05},
  howpublished = {https://www.nature.com/articles/s41588-023-01529-1},
  file = {/Users/xx20081/Zotero/storage/HIUHBC4A/s41588-023-01529-1.html}
}

@article{zhaoSodiumglucoseCotransporterInhibition2022,
  title = {Sodium-Glucose Cotransporter 1 Inhibition and Gout: {{Mendelian}} Randomisation Study},
  shorttitle = {Sodium-Glucose Cotransporter 1 Inhibition and Gout},
  author = {Zhao, Sizheng Steven and Rajasundaram, Skanda and Karhunen, Ville and Alam, Uazman and Gill, Dipender},
  year = {2022},
  month = oct,
  journal = {Seminars in Arthritis and Rheumatism},
  volume = {56},
  pages = {152058},
  issn = {0049-0172},
  doi = {10.1016/j.semarthrit.2022.152058},
  urldate = {2024-01-18},
  abstract = {Objective Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce serum urate, but their efficacy depends on renal function which is often impaired in people with gout. SGLT1 is primarily expressed in the small intestine and its inhibition may be a more suitable therapeutic target. We aimed to investigate the association of genetically proxied SGLT1i with gout risk, serum urate levels and cardiovascular safety using Mendelian randomisation (MR). Methods Leveraging data from a genome-wide association study of 344,182 individuals in the UK Biobank, we identified a missense variant in the SLC5A1 gene that associated with glycated haemoglobin (HbA1c) to proxy SGLT1i. Outcome genetic data comprised 13,179 gout cases and 750,634 controls, 457,690 individuals for serum urate levels, and up to 977,323 individuals for cardiovascular safety outcomes. We applied the Wald ratio method and investigated potential genetic confounding using colocalization. Results The rs17683430 missense variant was selected to instrument SGLT1i. Genetically proxied SGLT1i was associated with 75\% reduction in gout risk (OR 0.25; 95\%CI 0.06, 0.99; p~=~0.048) and 32.0~{$\mu$}mol/L reduction in serum urate (95\%CI -56.7, -7.3; p~=~0.01), per 6.7~mmol/mol reduction in HbA1c. SGLT1i was associated with increased levels of low-density lipoprotein cholesterol (0.37~mmol/L; 95\%CI 0.17, 0.56; p~=~0.0002) but not risk of coronary heart disease, stroke, or chronic kidney disease. Colocalization did not suggest that results are attributable to genetic confounding. Conclusion SGLT1 inhibition may represent a novel therapeutic option for preventing gout in people with or without comorbid diabetes. Randomised trials are needed to formally investigate efficacy and safety.},
  keywords = {Cholesterol,Diabetes,Glycated haemoglobin,Gout,SGLT1,Sodium-glucose cotransporter,Urate},
  file = {/Users/xx20081/Zotero/storage/RKI5FDX5/S0049017222001093.html}
}

@article{zhengEvaluatingEfficacyMechanism2022,
  title = {Evaluating the Efficacy and Mechanism of Metformin Targets on Reducing {{Alzheimer}}'s Disease Risk in the General Population: A {{Mendelian}} Randomisation Study},
  shorttitle = {Evaluating the Efficacy and Mechanism of Metformin Targets on Reducing {{Alzheimer}}'s Disease Risk in the General Population},
  author = {Zheng, Jie and Xu, Min and Walker, Venexia and Yuan, Jinqiu and {Korologou-Linden}, Roxanna and Robinson, Jamie and Huang, Peiyuan and Burgess, Stephen and Au Yeung, Shiu Lun and Luo, Shan and Holmes, Michael V. and Davey Smith, George and Ning, Guang and Wang, Weiqing and Gaunt, Tom R. and Bi, Yufang},
  year = {2022},
  month = oct,
  journal = {Diabetologia},
  volume = {65},
  number = {10},
  pages = {1664--1675},
  issn = {1432-0428},
  doi = {10.1007/s00125-022-05743-0},
  urldate = {2024-01-18},
  abstract = {Metformin use has been associated with reduced incidence of dementia in diabetic individuals in observational studies. However, the causality between the two in the general population is unclear. This study uses Mendelian randomisation (MR) to investigate the causal effect of metformin targets on Alzheimer's disease and potential causal mechanisms in the brain linking the two.},
  langid = {english},
  keywords = {Alzheimer's disease,Brain expression,Cognitive function,Dementia,Mendelian randomisation,Metformin targets,Mitochondrial function},
  file = {/Users/xx20081/Zotero/storage/LU6P3HXD/Zheng et al. - 2022 - Evaluating the efficacy and mechanism of metformin.pdf}
}
